Paradigm Medical Industries, Inc. (PDMI)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Paradigm Medical Industries, Inc. (PDMI). Paradigm Medical Industries, Inc. specializes in developing, manufacturing, and marketing medical devices for early glaucoma and eye disorder detection. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026Paradigm Medical Industries, Inc. (PDMI) Healthcare & Pipeline Overview
Paradigm Medical Industries, Inc. focuses on the niche market of diagnostic devices for early detection of glaucoma and other eye disorders. With a comprehensive product line including A-scans, pachymeters, and corneal topographers, the company caters to the U.S. market, facing competition from larger medical device manufacturers.
Investment Thesis
Paradigm Medical Industries operates in a specialized segment of the medical device market, focusing on early glaucoma and eye disorder detection. With a market capitalization of $0.00B and a negative P/E ratio of -0.01, the company's financial performance reflects challenges in achieving profitability, indicated by a -61.4% profit margin. However, a gross margin of 68.0% suggests potential in its product pricing and cost management. Key growth catalysts include expanding its product line and increasing market penetration in the U.S. Risks include intense competition and the need for continuous innovation to maintain market share. The company's high beta of -76.24 indicates high volatility relative to the market.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $0.00B reflects the company's small size and potential growth opportunities.
- P/E Ratio of -0.01 indicates the company is currently not profitable.
- Profit Margin of -61.4% highlights significant challenges in achieving profitability.
- Gross Margin of 68.0% suggests strong potential in product pricing and cost management.
- Beta of -76.24 indicates high volatility relative to the market.
Competitors & Peers
Strengths
- Specialized product portfolio focused on early glaucoma detection.
- Proprietary technology and patents.
- Established relationships with ophthalmologists and eye care professionals.
- Strong gross margin of 68.0%.
Weaknesses
- Small market capitalization of $0.00B.
- Negative profit margin of -61.4%.
- Limited geographic reach, primarily focused on the U.S.
- High beta of -76.24 indicating high volatility.
Catalysts
- Potential FDA approval for new diagnostic devices could expand market reach.
- Increasing prevalence of glaucoma and eye disorders driving demand for diagnostic tools.
- Strategic partnerships with hospitals and clinics enhancing distribution network.
Risks
- Intense competition from larger medical device manufacturers.
- Stringent regulatory requirements and approval processes.
- Technological obsolescence and the need for continuous innovation.
- Economic downturns affecting healthcare spending.
- OTC market risks, including low liquidity and limited disclosure.
Growth Opportunities
- Expanding Product Line: Paradigm Medical can drive growth by expanding its product line to include more advanced diagnostic tools and treatment options. The global market for ophthalmic devices is projected to reach $65 billion by 2028. Introducing innovative products, such as AI-powered diagnostic software or minimally invasive surgical devices, could attract new customers and increase revenue. Timeline: Launching 2-3 new products within the next 3 years.
- Increasing Market Penetration in the U.S.: Focusing on increasing market penetration within the United States represents a significant growth opportunity. The U.S. ophthalmic device market is the largest globally. By targeting specific regions or demographic groups with tailored marketing campaigns, Paradigm Medical can increase its customer base and sales. Timeline: Achieving a 10% increase in U.S. market share within 5 years.
- Strategic Partnerships and Collaborations: Forming strategic partnerships with hospitals, clinics, and eye care professionals can provide access to new markets and customers. Collaborating with research institutions to develop and commercialize new technologies can also drive growth. Timeline: Establishing 2-3 key partnerships within the next 2 years.
- Enhancing Software and Data Analytics Capabilities: Developing advanced software and data analytics tools to complement its hardware offerings can provide a competitive edge. By offering solutions that improve diagnostic accuracy and efficiency, Paradigm Medical can attract customers seeking comprehensive solutions. Timeline: Launching a new software platform within 3 years.
- Exploring International Markets: While currently focused on the U.S. market, exploring opportunities in international markets, particularly in Asia-Pacific and Europe, can drive long-term growth. These regions have a growing aging population and increasing prevalence of eye diseases, creating significant demand for diagnostic devices. Timeline: Entering 1-2 new international markets within 5 years.
Opportunities
- Expanding product line to include more advanced diagnostic tools.
- Increasing market penetration in the U.S.
- Forming strategic partnerships with hospitals and clinics.
- Exploring international markets in Asia-Pacific and Europe.
Threats
- Intense competition from larger medical device manufacturers.
- Stringent regulatory requirements and approval processes.
- Technological obsolescence and the need for continuous innovation.
- Economic downturns affecting healthcare spending.
Competitive Advantages
- Specialized Product Portfolio: Focus on niche market of early glaucoma and eye disorder detection.
- Proprietary Technology: Patents and intellectual property related to its diagnostic devices.
- Established Customer Relationships: Long-term relationships with ophthalmologists and eye care professionals.
- Brand Reputation: Reputation for quality and reliability in the eye care industry.
About PDMI
Founded in 1989, Paradigm Medical Industries, Inc. is dedicated to the development, manufacturing, and marketing of medical devices aimed at the early detection of glaucoma and other eye disorders. Headquartered in Salt Lake City, Utah, the company's product portfolio includes a variety of diagnostic tools such as the P-2000 biometric analyzer A-scans, P-2500 A-scans/pachymeters, P2700 A/B and P37-II A/B scans, and blood flow analyzers designed for managing glaucoma and retinal vascular disorders. Additionally, Paradigm Medical offers the P2200 pachymeter and P-2500 A-scan/pachymeters, as well as LD 500 and LD700 autoperimeters. The company also provides corneal topographers like PARAVUE 300 and SURVEYOR 500, PARAMAX for ganglion cell analysis, P60 and P60 ACI ultrasound biomicroscopes, and PARACAM 1000, a non-contact endothelial microscope, along with related software and accessories. Paradigm Medical primarily serves the United States market, providing essential tools for ophthalmologists and eye care professionals in the diagnosis and management of eye diseases.
What They Do
- Develops medical devices for early detection of glaucoma.
- Manufactures diagnostic equipment for eye disorders.
- Sells medical devices to ophthalmologists and eye care professionals.
- Markets products in the United States.
- Offers A-scans, pachymeters, and corneal topographers.
- Provides software and accessories for its medical devices.
- Creates blood flow analyzers for retinal vascular disorders.
Business Model
- Develops and manufactures medical devices for eye diagnostics.
- Sells directly to ophthalmologists, clinics, and hospitals.
- Generates revenue through product sales and accessories.
- Focuses on early detection of glaucoma and other eye disorders.
Industry Context
Paradigm Medical Industries operates within the medical instruments and supplies industry, a sector characterized by continuous innovation and stringent regulatory requirements. The market for glaucoma and eye disorder diagnostic devices is driven by an aging population and increasing prevalence of eye diseases. Competition is intense, with established players like Alcon and Topcon, as well as smaller specialized firms. Paradigm Medical's focus on early detection positions it within a growth segment, but it faces challenges in scaling and competing with larger companies with greater resources and broader product portfolios.
Key Customers
- Ophthalmologists
- Optometrists
- Hospitals
- Eye care clinics
- Medical research institutions
Financials
Chart & Info
Paradigm Medical Industries, Inc. (PDMI) stock price: Price data unavailable
Latest News
No recent news available for PDMI.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PDMI.
Price Targets
Wall Street price target analysis for PDMI.
MoonshotScore
What does this score mean?
The MoonshotScore rates PDMI's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Charles S. Pritchard
CEO
Charles S. Pritchard serves as the CEO of Paradigm Medical Industries, Inc. He oversees the company's operations, strategic direction, and product development. With experience in managing small teams, Pritchard is responsible for guiding the company's efforts in the competitive medical device market. His leadership is crucial for navigating the challenges of a small company in a highly regulated industry.
Track Record: Under Charles S. Pritchard's leadership, Paradigm Medical Industries has continued to develop and market diagnostic devices for early glaucoma detection. Key milestones include maintaining a strong gross margin despite overall profitability challenges. His focus remains on expanding the company's product line and increasing market penetration within the United States.
PDMI OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Paradigm Medical Industries may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting, and trading can be more speculative. This tier is often associated with higher risk due to the lack of stringent listing requirements and potential for less transparency compared to companies listed on major exchanges like the NYSE or NASDAQ. Investors should exercise caution and conduct thorough due diligence before investing in companies on the OTC Other tier.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Financial Disclosure: Lack of comprehensive financial reporting increases investment risk.
- Low Liquidity: Low trading volume and wide bid-ask spreads can lead to price volatility.
- Speculative Nature: OTC Other stocks are often more speculative due to less stringent listing requirements.
- Potential for Fraud: Higher risk of fraud and manipulation compared to listed exchanges.
- Regulatory Scrutiny: Increased regulatory scrutiny and potential for delisting.
- Verify Management Team: Confirm the background and experience of the management team.
- Review Financial Statements: Obtain and review any available financial statements.
- Assess Business Model: Understand the company's business model and revenue streams.
- Check Regulatory Filings: Review any available regulatory filings and disclosures.
- Evaluate Market Position: Assess the company's competitive position in the market.
- Monitor News and Developments: Stay informed about any news or developments related to the company.
- Consult Financial Advisor: Seek advice from a qualified financial advisor.
- Years in Operation: Founded in 1989, indicating a long operating history.
- Specialized Product Portfolio: Focus on a niche market of early glaucoma detection.
- Proprietary Technology: Patents and intellectual property related to its diagnostic devices.
- Established Customer Relationships: Relationships with ophthalmologists and eye care professionals.
- Headquarters in Salt Lake City, Utah: Physical presence and operations in the United States.
PDMI Healthcare Stock FAQ
What does Paradigm Medical Industries, Inc. do?
Paradigm Medical Industries, Inc. specializes in the development, manufacturing, and marketing of medical devices for the early detection of glaucoma and other eye disorders. The company offers a range of diagnostic equipment, including A-scans, pachymeters, blood flow analyzers, and corneal topographers. These products are primarily sold to ophthalmologists, optometrists, hospitals, and eye care clinics in the United States, providing essential tools for diagnosing and managing eye diseases.
What do analysts say about PDMI stock?
As of March 17, 2026, there is limited analyst coverage for Paradigm Medical Industries, Inc. (PDMI) due to its OTC listing and small market capitalization. Key valuation metrics include a negative P/E ratio of -0.01 and a profit margin of -61.4%, indicating challenges in achieving profitability. However, a gross margin of 68.0% suggests potential in its product pricing and cost management. Investors should conduct thorough due diligence and consider the risks associated with OTC stocks before investing.
What are the main risks for PDMI?
The main risks for Paradigm Medical Industries, Inc. include intense competition from larger medical device manufacturers, stringent regulatory requirements and approval processes, and the need for continuous innovation to avoid technological obsolescence. Additionally, the company faces risks associated with its OTC listing, including low liquidity, limited financial disclosure, and potential for price volatility. Economic downturns affecting healthcare spending also pose a risk to the company's financial performance.
How does Paradigm Medical Industries, Inc. navigate regulatory approval processes?
As a medical device company, Paradigm Medical Industries, Inc. must adhere to stringent regulatory requirements set by the FDA to ensure the safety and efficacy of its products. The company's strategy involves rigorous testing, documentation, and compliance with quality management systems. Delays in regulatory approvals can significantly impact product launch timelines and market access, representing a key risk factor. Maintaining compliance and proactively engaging with regulatory bodies are crucial for Paradigm Medical's success.
How does Paradigm Medical Industries, Inc. compete with larger medical device companies?
Paradigm Medical Industries, Inc. competes with larger medical device companies by focusing on a niche market of early glaucoma and eye disorder detection. This specialization allows the company to develop targeted products and build strong relationships with ophthalmologists and eye care professionals. Additionally, Paradigm Medical relies on proprietary technology and patents to differentiate its products and maintain a competitive edge. Strategic partnerships and collaborations also help the company expand its reach and access new markets.
What are the key factors to evaluate for PDMI?
Evaluating PDMI involves reviewing fundamentals, analyst consensus, and risk factors. Key strength: Specialized product portfolio focused on early glaucoma detection. Primary risk to monitor: Intense competition from larger medical device manufacturers. This is not financial advice.
How frequently does PDMI data refresh on this page?
PDMI prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven PDMI's recent stock price performance?
Recent price movement in Paradigm Medical Industries, Inc. (PDMI) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Specialized product portfolio focused on early glaucoma detection. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is limited due to the company's OTC listing and lack of comprehensive reporting.
- Analyst coverage is minimal, requiring investors to conduct independent research.